Table 1.

Patient characteristics

ID	Diagnosis	Sex	Age, y	Previous chemotherapy	Cytogenetic risk group*	IPSS	Best response
1	AML-TLD	M	38	No	Poor	NA	CR
2	AML-TLD	M	78	No	Poor	NA	NR
3	AML-TLD	F	63	No	Poor	NA	NR
4	MDS	M	43	No	Good	INT-1	CR
5	MDS	M	61	No	Poor	INT-2	NR
6	MDS	M	79	No	Good	INT-1	NR
7	MDS	F	64	No	Good	INT-2	PR
8	MDS	M	84	No	Good	INT-1	NR
9	AML-TLD	F	55	No	Good	NA	NR
10	AML-relapse	M	67	No	Poor	NA	PR
11	CMMoL	F	61	No	Good	INT-1	HI
12	MDS	M	66	No	Intermediate	INT-2	HI
13	MDS	M	74	No	Intermediate	INT-2	HI
14	MDS	F	61	No	Good	INT-2	NR
15	AML-refractory	F	35	Yes	Poor	NA	NR
16	AML-TLD	M	83	No	Good	NA	PR
17	MDS	M	74	No	Good	INT-1	HI
18	MDS	M	75	No	Good	INT-2	HI
19	MDS	M	52	No	Intermediate	INT-1	NR
20	AML-TLD	M	70	Yes	Good	NA	HI
21	AML-refractory	F	58	Yes	Intermediate	NA	NR
22	MDS	M	59	No	Good	INT-1	PR
23	CMMoL	M	65	No	Poor	NA†	NR
24	CMMoL	M	55	No	Intermediate	INT-1	NR
25	MDS	M	51	No	Good	INT-2	NR
26	AML-TLD	M	61	No	Intermediate	NA	NR
27	CMMoL	M	69	No	Intermediate	NA†	NR
28	AML-TLD	F	48	Yes	Good	NA	CR
29	AML-TLD	F	65	No	Intermediate	NA	HI
30	MDS	M	78	Yes	Intermediate	High	NR

AML-TLD indicates AML with trilineage dysplasia; CMMoL, chronic myelomonocytic leukemia; NA, not applicable; INT-1, intermediate-1; INT-2, intermediate-2; and IPSS, International Prognostic Scoring System.

^*Cytogenetic risk group assigned per IPSS categorization.

^†CMMoL patients with white blood cell count more than 12 × 10⁹ monocytes/L (121000/μL) were not given an IPSS score.